Direkt zum Inhalt
Merck
  • Supermolecular inclusion of piroxicam with beta-cyclodextrin: a review of its pharmacological properties in laboratory animals.

Supermolecular inclusion of piroxicam with beta-cyclodextrin: a review of its pharmacological properties in laboratory animals.

European journal of rheumatology and inflammation (1993-01-01)
R E Lister, D Acerbi, S Cadel
ZUSAMMENFASSUNG

Piroxicam-beta-cyclodextrin is a novel NSAID; it is a supermolecular inclusion complex designed to improve the risk:benefit ratio of piroxicam. In animal studies it has been shown to be as effective as piroxicam as an anti-inflammatory and analgesic agent but with a more rapid onset of action and reduced gastropathic effects.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Piroxicam, ≥98% (TLC)
USP
Piroxicam, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Piroxicam, meets USP testing specifications
Piroxicam für die Systemeignung, European Pharmacopoeia (EP) Reference Standard
Piroxicam, European Pharmacopoeia (EP) Reference Standard